ACADIA Pharmaceuticals In...

16.63
0.31 (1.90%)
At close: Apr 02, 2025, 3:59 PM
16.62
-0.06%
After-hours: Apr 02, 2025, 05:36 PM EDT

ACADIA Pharmaceuticals Statistics

Share Statistics

ACADIA Pharmaceuticals has 166.79M shares outstanding. The number of shares has increased by 0.95% in one year.

Shares Outstanding 166.79M
Shares Change (YoY) 0.95%
Shares Change (QoQ) 0.24%
Owned by Institutions (%) 98.05%
Shares Floating 165.49M
Failed to Deliver (FTD) Shares 249
FTD / Avg. Volume 0.01%

Short Selling Information

The latest short interest is 17.12M, so 10.29% of the outstanding shares have been sold short.

Short Interest 17.12M
Short % of Shares Out 10.29%
Short % of Float 10.42%
Short Ratio (days to cover) 4.09

Valuation Ratios

The PE ratio is 13.43 and the forward PE ratio is 23.45. ACADIA Pharmaceuticals's PEG ratio is -0.03.

PE Ratio 13.43
Forward PE 23.45
PS Ratio 3.17
Forward PS 1.8
PB Ratio 4.15
P/FCF Ratio 19.34
PEG Ratio -0.03
Financial Ratio History

Enterprise Valuation

ACADIA Pharmaceuticals has an Enterprise Value (EV) of 2.77B.

EV / Sales 2.9
EV / EBITDA 27.69
EV / EBIT 17.58
EV / FCF 17.64

Financial Position

The company has a current ratio of 2.38, with a Debt / Equity ratio of 0.07.

Current Ratio 2.38
Quick Ratio 2.32
Debt / Equity 0.07
Debt / EBITDA 0.52
Debt / FCF 0.33
Interest Coverage 0

Financial Efficiency

Return on Equity is 30.9% and Return on Invested Capital is 25.22%.

Return on Equity 30.9%
Return on Assets 19.07%
Return on Invested Capital 25.22%
Revenue Per Employee $1.47M
Profits Per Employee $346.79K
Employee Count 653
Asset Turnover 0.81
Inventory Turnover 3.73

Taxes

Income Tax 31.62M
Effective Tax Rate 12.25%

Stock Price Statistics

The stock price has increased by -9.72% in the last 52 weeks. The beta is 0.43, so ACADIA Pharmaceuticals's price volatility has been higher than the market average.

Beta 0.43
52-Week Price Change -9.72%
50-Day Moving Average 18.22
200-Day Moving Average 16.89
Relative Strength Index (RSI) 39.19
Average Volume (20 Days) 1.89M

Income Statement

In the last 12 months, ACADIA Pharmaceuticals had revenue of 957.8M and earned 226.45M in profits. Earnings per share was 1.37.

Revenue 957.8M
Gross Profit 875.96M
Operating Income 230.79M
Net Income 226.45M
EBITDA 100.16M
EBIT 84.28M
Earnings Per Share (EPS) 1.37
Full Income Statement

Balance Sheet

The company has 319.59M in cash and 51.99M in debt, giving a net cash position of 267.59M.

Cash & Cash Equivalents 319.59M
Total Debt 51.99M
Net Cash 267.59M
Retained Earnings -2.2B
Total Assets 1.19B
Working Capital 543.45M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 157.72M and capital expenditures -523K, giving a free cash flow of 157.2M.

Operating Cash Flow 157.72M
Capital Expenditures -523K
Free Cash Flow 157.2M
FCF Per Share 0.95
Full Cash Flow Statement

Margins

Gross margin is 91.46%, with operating and profit margins of 24.1% and 23.64%.

Gross Margin 91.46%
Operating Margin 24.1%
Pretax Margin 26.94%
Profit Margin 23.64%
EBITDA Margin 10.46%
EBIT Margin 24.1%
FCF Margin 16.41%

Dividends & Yields

ACAD does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield 7.45%
FCF Yield 5.17%
Dividend Details

Analyst Forecast

The average price target for ACAD is $23, which is 38.3% higher than the current price. The consensus rating is "Buy".

Price Target $23
Price Target Difference 38.3%
Analyst Consensus Buy
Analyst Count 16
Stock Forecasts

Scores

Altman Z-Score 2.64
Piotroski F-Score 3